Valye reports for unlimited access

Tigo Energy, Inc. operates in the solar energy sector, focusing on the design, development, and sale of solar hardware products, including Module Level Power Electronics (MLPE) and energy storage systems (GO ESS). The company also offers a SaaS platform called Predict+ and web-based monitoring services. Revenue is primarily generated through hardware sales to distributors, with additional income from royalties and software services. The company’s operations are global, with significant revenue contributions from EMEA, Americas, and APAC regions. Tigo Energy’s business model relies on contract manufacturing, with production concentrated in Thailand, China, and Vietnam, and it is subject to tariffs on imports into the U.S. The company is actively expanding its residential market presence in the U.S. and EMEA and investing in research and development to support new product introductions.

ACCESS Newswire Inc. is a company focused on press release distribution and related communications services. Its primary revenue driver is the ACCESSWIRE newswire brand, supplemented by sister platforms Newswire.com and PressRelease.com. The company has undergone growth through acquisitions and product enhancements, including virtual event products developed during the COVID-19 pandemic. It sold its Compliance business in February 2025, reallocating proceeds to debt reduction. The company recognizes subscription and service contract revenues ratably over contract terms, which can delay the impact of sales fluctuations on reported results. It operates in a highly competitive environment with competitors possessing greater resources and longer histories. The company has expanded its workforce significantly since 2012 and continues to invest in sales, marketing, and technology development. It is subject to various operational, competitive, regulatory, and financial risks, including those related to technology reliability, data security, and managing growth and acquisitions.

Research Frontiers Inc. develops and licenses patented SPD-Smart light-control technology used in various applications including aerospace, architectural, automotive, marine, and display products. The company licenses its technology to over 40 licensees worldwide, generating revenue primarily through license fees and royalties. Revenue recognition is based on three performance obligations: the grant of use of its patent portfolio, stand-ready technical support, and access to new intellectual property. The company’s royalty income is influenced by automotive industry trends and the adoption of SPD-SmartGlass technology in vehicle models. The company operates as a single segment and reports consolidated financial results. It has incurred recurring losses but maintains liquidity through equity financing and royalty collections. The company’s assets include property, equipment, and operating lease right-of-use assets located in the United States. It has a global revenue base with a majority generated outside the U.S.

Solid Biosciences Inc. focuses on developing gene therapies targeting rare genetic neuromuscular and cardiac diseases. Its pipeline includes candidates SGT-003, SGT-212, and SGT-501, with ongoing clinical trials such as INSPIRE DUCHENNE and IMPACT DUCHENNE. The company has received FDA orphan drug designations and fast track status for some candidates. It has not yet generated product revenue and continues to incur net losses. Solid Biosciences maintains strong liquidity as of the end of 2025 but anticipates the need for additional funding to advance its clinical programs and commercialization efforts. The company currently lacks internal sales and marketing infrastructure and may seek partnerships for commercialization.

Sky Harbour Group Corp is an aviation infrastructure developer focused on creating a nationwide network of Home Base Operator (HBO) campuses designed exclusively for business aircraft. The company develops, leases, and manages private and semi-private hangars at airports with significant based aircraft populations and high demand for hangar space. Its proprietary hangar designs accommodate larger jets with taller tail heights and winglets, addressing a shortage in suitable hangar infrastructure. Revenues derive mainly from long-term rental agreements, providing stable cash flows. As of December 31, 2025, the company operated 61 hangars totaling over 1 million rentable square feet with 78.1% occupancy and had 74 hangars under development or construction. The company finances development through bonds and bank debt and manages a diversified tenant base with staggered lease maturities.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company that develops novel biologic therapeutic candidates using proprietary modular protein engineering platforms. The company was spun off from Inhibrx, Inc. in May 2024, acquiring assets related to its clinical programs and discovery pipeline. Its current clinical pipeline includes ozekibart (INBRX-109), a tetravalent DR5 agonist targeting cancer cells to induce apoptosis, and INBRX-106, a hexavalent OX40 agonist designed to enhance T-cell co-stimulation and anti-tumor immunity. Ozekibart is being investigated in multiple oncology indications including chondrosarcoma, Ewing sarcoma, and colorectal cancer, with positive clinical trial data reported. INBRX-106 is in early clinical development for solid tumors such as non-small cell lung cancer and head and neck squamous cell carcinoma. The company maintains in-house capabilities across discovery, protein engineering, clinical development, and commercialization, supported by a leadership team with extensive industry experience. Inhibrx reported $1.3 million in revenue and a net loss of $140.1 million for the fiscal year ended December 31, 2025, with a strong liquidity position and outstanding debt secured by company assets. The company is exploring strategic options for its lead program ozekibart to maximize value and accelerate development.

United States Antimony Corp is a mining and processing company focused on antimony, precious metals (gold and silver), and zeolite. It operates vertically integrated antimony processing facilities in Montana and Mexico, and a zeolite mining and processing facility in Idaho. The company has been expanding its mining claims in Alaska, Montana, Canada, and the southeastern U.S. It supplies antimony products used in flame retardants, batteries, ordnance, and other industrial applications primarily to customers in the U.S. and Canada. The company secured significant multi-year contracts in 2025, including a $248 million IDIQ contract with the U.S. Defense Logistics Agency. It is expanding processing capacity to support these contracts and has received government funding to modernize domestic production. The company’s stock began trading on the NYSE in March 2026. Financially, the company reported $39.3 million in revenues and a net loss of $4.3 million for 2025, with strong liquidity and increased working capital.

SELLAS Life Sciences Group, Inc. operates as a single segment biotechnology company focused on the development of novel therapeutics for cancer indications. The company’s clinical programs include the development of SLS009 and GPS, targeting acute myeloid leukemia and other cancers. SELLAS holds exclusive licenses for key technologies, including from GenFleet Therapeutics and Memorial Sloan Kettering Cancer Center, with milestone and royalty obligations contingent on development and sales outcomes. The company’s financial position as of December 31, 2025, shows a strong liquidity profile with over $71 million in cash and equivalents and a current ratio above 10, supporting ongoing clinical development activities. SELLAS has reported recurring net losses and negative cash flows from operations, consistent with its clinical-stage status. Recent strategic agreements and clinical trial progress have been publicly disclosed, reflecting active advancement of its pipeline.

Galecto, Inc. is a clinical-stage biopharmaceutical company engaged in developing treatments primarily for oncology, liver diseases, and rare diseases such as acute myeloid leukemia (AML). The company has undergone strategic shifts focusing on clinical-stage compounds including GB1211 and has acquired global rights to BRM-1420 and GB3226. In late 2025, Galecto completed a business combination with Damora Therapeutics, Inc., and subsequently changed its corporate name. The company has raised capital through a $275 million public offering in early 2026 to support its operations and clinical development programs. Financial disclosures indicate strong liquidity and ongoing net losses consistent with clinical-stage biopharmaceutical companies. The company is subject to typical industry risks including clinical development, regulatory approvals, and potential legal matters.

Harvard Apparatus Regenerative Technology, Inc. is a biotechnology company with two main operating segments: Regenerative Biotech, which focuses on developing regenerative medicine treatments for cancers, injuries, and birth defects of the gastrointestinal tract and airways, and Consumer Health Products, which markets dietary supplements primarily in Asia. The company’s consumer health products are distributed globally through an exclusive agreement with Health Regen, Inc. Revenue is recognized primarily upon delivery or availability of goods to customers or distributors. The company incurs research and development expenses related to its regenerative biotech segment and maintains manufacturing and office facilities in Holliston, MA. The company’s operations are subject to regulatory oversight by the FDA and foreign authorities, with associated compliance risks. The company reported product revenue of $704,000 in 2025, all from consumer health products, and a net loss of $6.87 million for the year ended December 31, 2025. Cash and short-term investments totaled approximately $2.55 million at year-end 2025, with a current ratio of 1.19. The company has ongoing clinical trials and research collaborations to advance its regenerative medicine pipeline.

electroCore, Inc. develops and commercializes bioelectronic therapies, including prescription devices such as gammaCore and Quell, targeting conditions like fibromyalgia and general wellness. The company has recently expanded its product portfolio to include general wellness and human performance products marketed under brands like Truvaga and TAC-STIM. Its sales are heavily concentrated in government healthcare channels, especially the U.S. Department of Veterans Affairs. electroCore relies on third-party manufacturers and distributors, including sole-source suppliers, for critical components and distribution outside the U.S. The company is actively expanding its direct-to-consumer sales channels and investing in commercial infrastructure to support growth. However, it faces challenges related to market acceptance, reimbursement coverage, supply chain reliability, and financial sustainability.

Eastern Company, incorporated in 1912, designs, manufactures, and sells engineered solutions primarily serving commercial transportation and logistics markets. It operates one reportable segment, Engineered Solutions, which includes subsidiaries producing custom vehicular hardware, packaging solutions, security hardware, and vision technology. The company maintains 14 locations across North America and Asia and employs approximately 1,246 people globally. Eastern competes in a global market with pricing pressures from imports and raw material cost fluctuations influenced by tariffs and trade policies. The company manages financial and operational performance with a focus on cash generation, cost discipline, and strategic growth through organic initiatives and acquisitions. Recent divestitures include the sale of a division of Big 3 Mold in 2025. The company’s financials for fiscal 2026 show revenues near $249 million and net income of $7.1 million, with liquidity ratios indicating a strong current position.

Zion Oil & Gas, Inc. is a Texas-based oil and gas exploration company with a 25-year focus on onshore exploration in Israel. The company operates through wholly owned subsidiaries that own drilling rigs and provide drilling services. Zion holds exploration licenses granted by the Israeli government, including the Megiddo Valleys License 434, which covers approximately 75,000 acres and is valid through 2026 with potential extensions. The company’s exploration activities center on the MJ-01 and MJ-02 wells, where recent recompletion and stimulation operations have resulted in gas reaching the surface, indicating a potentially productive reservoir. Zion’s operations have been affected by regional geopolitical conflicts, visa and logistical challenges, and regulatory requirements. The company currently has no revenues and funds its operations primarily through equity financing. As of the end of 2025, Zion had a strong liquidity position but reported net losses consistent with its exploratory stage.

Westwater Resources, Inc. operates as an energy technology company specializing in the development of battery-grade natural graphite materials. Its primary assets include the Kellyton Graphite Plant, a processing facility under construction in Alabama, and the Coosa Graphite Deposit, a graphite mineral exploration project also in Alabama. The Kellyton Plant is designed to produce ULTRA-CSPG™ and SG Fines graphite products primarily for lithium-ion battery applications. The company uses a proprietary purification process that avoids hydrofluoric acid, aiming for a lower environmental footprint. Westwater sources graphite concentrate from Syrah Resources Limited and a backup supplier until its own mining operations commence. The company has entered into offtake agreements with SK On and Hiller Carbon, while FCA terminated its offtake agreement in 2025. Westwater is in the exploration and permitting phase for the Coosa Deposit and continues construction and capital planning for the Kellyton Plant. The company is in the development stage, with no recorded revenue from graphite operations, and reports ongoing net losses. It maintains liquidity through convertible notes and equity offerings and holds all necessary permits for Phase I construction. Westwater emphasizes safety, environmental stewardship, and community engagement as core values.

Five Below, Inc. is a specialty value retailer founded in 2002 and headquartered in Philadelphia, Pennsylvania. The company operates a chain of approximately 1,921 stores across 46 states as of January 31, 2026, primarily located in power, community, and lifestyle shopping centers. Its stores offer a dynamic assortment of trend-right, high-quality products, mostly priced at $5 and below, organized into eight category worlds: Candy, Style, Party, Room, Create, Tech, Sports, and New & Now. The company also operates an e-commerce platform with home delivery and buy online pick up in store options. Five Below targets a broad demographic, including children and young consumers, with a focus on providing an engaging and fun shopping experience. The company has demonstrated growth in store count and net sales over recent years and maintains a strong liquidity position as of the latest reporting period.

SailPoint, Inc. specializes in enterprise identity security, providing solutions that unify and govern identities across humans, machines, and AI agents. Its flagship offering, the Identity Security Cloud, is a multi-tenant SaaS platform powered by AI and automation to deliver real-time adaptive identity governance. The company also offers IdentityIQ, a customer-hosted solution for organizations not ready for SaaS. SailPoint's platform supports lifecycle management, compliance, access modeling, analytics, and specialized modules for agent and machine identity security, data access, privileged task automation, and cloud infrastructure entitlement management. The company serves a broad global customer base of over 3,200 organizations across multiple industries and geographies. Its go-to-market approach combines direct sales with an extensive partner ecosystem including system integrators, managed service providers, and value-added resellers. SailPoint invests heavily in R&D to maintain innovation leadership, particularly in AI capabilities. Financially, the company reported a net loss in fiscal 2026 but maintains a solid liquidity position with over $350 million in cash and equivalents and a current ratio above 1.3. The company faces risks typical of a rapidly growing technology firm, including competitive pressures, regulatory compliance challenges, and integration risks from acquisitions.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing new chemical entities and novel drug formulations targeting high unmet medical needs in cancer and neurological disorders. The company underwent a strategic shift in 2024-2025, terminating development of esmethadone and REL-P11, and acquiring/licensing two lead candidates: NDV-01, a controlled-release intravesical chemotherapy formulation for non muscle-invasive bladder cancer, and sepranolone, a neurosteroid targeting GABAergic pathways for neurological disorders such as Prader-Willi syndrome and Tourette Syndrome. NDV-01 is in Phase 2 clinical trials with positive safety and efficacy data at 12 months, and Phase 3 trials are planned for mid-2026. Sepranolone demonstrated promising Phase 2a results in Tourette Syndrome and is preparing for a Phase 2b study in Prader-Willi syndrome. The company has no commercial products or revenues and reported a net loss of $57.4 million for 2025. It maintains a strong liquidity position with approximately $93 million in cash and short-term investments as of December 31, 2025. Relmada relies on third parties for clinical trials and manufacturing and faces competition from larger pharmaceutical companies. The company holds substantial intellectual property portfolios for its lead candidates, potentially extending protection beyond 2038.

Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases by inhibiting Tyrosine Kinase 2 (TYK2). Its lead product candidate, envudeucitinib (envu), is a second-generation TYK2 inhibitor undergoing pivotal Phase 3 trials for moderate-to-severe plaque psoriasis, with positive topline results announced in early 2026. Envudeucitinib is also in Phase 2 development for systemic lupus erythematosus (SLE). The company’s pipeline includes A-005, a CNS-penetrant allosteric TYK2 inhibitor in early clinical development, and lonigutamab, a monoclonal antibody acquired through merger targeting Thyroid Eye Disease. Alumis does not own manufacturing facilities and relies on third-party contract manufacturers, with plans to establish redundant supply chains. The company is building commercial infrastructure and exploring partnerships to support potential product launches in key global markets. Alumis operates as a single reportable segment focused on autoimmune disorder therapeutics.

Terra Property Trust, Inc. operates as a real estate investment trust that originates, invests in, and manages a portfolio of commercial real estate credit assets in the United States. The company focuses on middle market loans ranging from $10 million to $50 million, which include first mortgage loans, subordinated loans (such as mezzanine and preferred equity), and credit facilities. Its portfolio spans multiple property types including multifamily housing, student housing, commercial offices, retail, mixed-use, and infill properties, diversified across several states. The company is externally managed by Mavik Capital Management, LP, a subsidiary of Terra Capital Partners, which has a 20-year track record in real estate credit investment management. Terra Property Trust aims to generate attractive risk-adjusted returns primarily through current income and preservation of capital, with occasional strategic equity and non-real estate investments. The company uses moderate leverage and various financing sources, including unsecured notes and secured borrowings, and continues to explore liquidity options such as a direct listing or strategic business combinations.

CSLM Digital Asset Acquisition Corp III, Ltd is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in July 2024. Its purpose is to identify and complete a business combination with one or more companies primarily in sectors related to digital assets, Web3, financial services infrastructure, and blockchain technologies, with a focus on emerging and frontier markets. The company completed its initial public offering in August 2025, raising gross proceeds of $230 million, plus an additional $8.9 million from a private placement. The proceeds are held in a trust account to be used for the initial business combination. The company has not generated operating revenues and has only engaged in organizational and IPO-related activities. It announced a non-binding letter of intent with First Digital Group Ltd., a stablecoin and digital asset infrastructure provider, for a potential business combination. The company’s sponsor and affiliates provide advisory and administrative support leveraging extensive experience in frontier markets and ESG investing. The company has a 24-month window from IPO to complete a business combination, with possible extensions subject to shareholder approval.

Gambling.com Group Ltd is an online gambling affiliate and data services company that generates revenue primarily through marketing and data subscription services. Its marketing revenue includes performance marketing fees such as CPA, revenue share, hybrid models, and ticketing commissions. Data revenue is derived from consumer and enterprise subscriptions for sports data and analytics. The company operates globally with significant revenue from North America, UK and Ireland, Europe, and other regions. It has grown through acquisitions including OddsJam, Spotlight.Vegas, and Freebets.com Assets, which have contributed to revenue expansion. The business is subject to seasonality linked to sports events and casino product cycles. The company holds a portfolio of domain names and trademarks critical to its brand identity. Financially, the company reported $165.4 million in revenue for 2025 but incurred a net loss of $32.9 million, influenced by acquisition-related costs and impairments. Liquidity and working capital levels are sufficient to support ongoing operations, and the company complies with its debt covenants. Market risks include regulatory changes, competition, and reliance on search engine visibility for customer acquisition.

MultiSensor AI Holdings, Inc. develops and deploys integrated condition monitoring and early threat detection solutions that combine multiple sensor types with a unified edge-to-cloud software platform called MSAI Connect. The company’s hardware portfolio includes visible, infrared, ultraviolet, acoustic, and laser-based sensors, often combined in multi-sensor devices. These sensors feed data into the MSAI Connect SaaS platform, which continuously monitors critical assets across electrical, mechanical, and environmental systems to identify early signs of degradation and enable proactive maintenance. The company targets commercial environments with high automation intensity such as distribution and parcel logistics, data centers, and manufacturing facilities. It is transitioning from a transactional hardware sales model to a subscription-based SaaS platform, aiming to increase recurring revenue through software attachment and expanded sensor deployments. Sales are conducted both directly and through a network of channel partners. As of December 31, 2025, the company had approximately 730 active sensors connected, a 59% increase year-over-year. Financially, the company reported a net loss of $11.7 million for the fiscal year ended December 31, 2025, with strong liquidity evidenced by $24.4 million in cash and equivalents and a current ratio of 11.66. The business is primarily US-based with a significant customer concentration in the distribution and logistics market.

Intuitive Machines, Inc. is a space infrastructure and services company founded in 2013, focused on enabling sustained infrastructure and human activity beyond Earth, with an initial emphasis on the Moon and cislunar space. The company operates under a Build-Connect-Operate model: it designs, manufactures, and delivers spacecraft, landers, satellites, and propulsion systems (Build); integrates these assets into communications, navigation, and data relay networks (Connect); and provides mission operations and infrastructure-as-a-service offerings (Operate). This integrated approach aims to transition space activity from finite missions to continuously operating infrastructure, supporting recurring revenue opportunities and margin expansion over time [S1].

Spire Global, Inc. is a provider of space-based data, analytics, and space services using a proprietary constellation of LEMUR nanosatellites. The company designs, manufactures, and operates its satellites and ground stations to collect radio frequency data globally. Its offerings include clean, smart, predictive data, and data solutions across verticals such as space reconnaissance, aviation, weather and climate, and space services. Spire's platform supports real-time monitoring, signal detection, and analytics for government and commercial customers. The company completed the sale of its maritime business in 2025 and focuses on expanding its satellite constellation and data capabilities. It operates a global network of over 30 ground stations and employs a direct sales model with a land-and-expand approach. Research and development efforts focus on enhancing the space platform and data solutions. Spire faces competition from specialized companies in its verticals and operates in a fragmented, rapidly evolving market.

Eledon Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company developing therapies primarily focused on organ transplantation and ALS. The company’s lead product candidate, tegoprubart, is in clinical trials targeting kidney and liver transplant rejection. Eledon has no commercial products and has historically incurred net losses due to research and development and general administrative expenses. The company finances its operations through equity offerings and maintains a strong liquidity position with cash, cash equivalents, and short-term investments totaling approximately $133 million as of the end of 2025. Eledon’s operations are concentrated in the United States, with leased office facilities in California and Massachusetts. The company’s management evaluates performance on a consolidated basis and allocates resources across its single operating segment focused on clinical development [S1][S19].

Columbus Acquisition Corp is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in January 2024. Its business model is to identify and complete a merger, share exchange, asset acquisition, or similar business combination with one or more target businesses. The company completed its IPO in January 2025, issuing 6 million units at $10 each, with proceeds held in a trust account. It has no operating revenue and has incurred losses related to formation and operating expenses. The company’s management has discretion over the use of IPO proceeds outside the trust account, primarily to consummate a business combination and for working capital. In November 2025, the company entered into a business combination agreement with WISeSat.Space Holdings Corp., a subsidiary of WISeKey International Holding AG, to publicly list WISeSat.Space Corp. under the name WISeSat.Space Holdings Corp. The company has the ability to extend the deadline to complete the business combination up to twelve times by one-month increments, potentially extending the deadline to January 22, 2027. The Sponsor holds approximately 21.83% of the company’s shares. The company’s financial statements show a current ratio of 1.58 as of December 31, 2025, and net income of $1,285,090 for the fiscal year ended December 31, 2025.

Bakkt, Inc. builds digital financial infrastructure to support institutional adoption of digital asset trading, stablecoin payments, and related financial services. The company operates through Bakkt Financial Solutions I, LLC, providing clients with a platform to enable their customers to transact in digital assets. Bakkt's platform offers institutional-grade trading, custody, payment, and compliance capabilities, supported by extensive regulatory licenses across the United States. The company focuses on three core solutions: Bakkt Markets for brokerage and trading services, Bakkt Agent for programmable financial infrastructure access, and Bakkt Global for international expansion through strategic investments. Bakkt's business model relies on licensing front-end trading platforms to clients, who then offer digital asset services to their customers. The company has been executing a strategic transformation since 2025, including divesting non-core assets, simplifying its corporate structure, and investing in core platform infrastructure. Key recent corporate actions include the sale of its Loyalty business, acquisition of DTR, and a registered direct offering to raise capital.

Avalon Holdings Corporation, established in 1998 as a spin-off from American Waste Services, operates two main business segments: waste management services and golf and related operations. The waste management segment provides hazardous and nonhazardous waste disposal brokerage and management, captive landfill management, and salt water injection well operations primarily in selected northeastern and midwestern U.S. markets. The golf and related operations segment manages four golf courses, country clubs, a hotel resort (The Grand Resort), fitness centers, tennis courts, salon and spa services, and a dermatology center. Avalon owns several subsidiaries that operate these facilities and services, including Avalon Med Spa, LLC and Avalon Dermatology, LLC, which are majority-owned variable interest entities. The company’s revenue mix in 2025 was approximately 55% from waste management services and 45% from golf and related operations. Avalon’s operations emphasize regulatory compliance, customer service, and facility management. The company faces challenges in member retention and acquisition in its golf operations and manages customer concentration risks in its waste management segment. Financially, Avalon reported net income of $321,000 for the fiscal year ending December 31, 2025, with a current ratio of 1.01 indicating tight liquidity. The company is listed on the NYSE American exchange under the ticker AWX.

NovaBay Pharmaceuticals, Inc. historically developed and sold eyecare, wound care, and skin care products but has significantly reduced these operations through asset divestitures completed by early 2025. The company has shifted its business model to focus on acquiring and holding digital assets, primarily SKY tokens, as part of a capital allocation strategy targeting economic participation in open digital financial networks. The company completed a private placement in January 2026, raising approximately $137.4 million in cash and digital assets to support this strategy. NovaBay holds its digital assets with multiple U.S.-based custodians and maintains internal controls and risk management policies to safeguard these assets. The company reported a net loss and negative earnings per share for the fiscal year ended 2025, reflecting the transition period and reduced legacy operations. NovaBay's liquidity position remains strong with substantial cash and equivalents relative to current liabilities.

CIMG Inc. develops and markets Maca-based products targeting consumers in Asia for everyday use. The company’s product portfolio is concentrated in the Maca Series, with limited diversification. It relies heavily on a small number of suppliers and customers, with two suppliers accounting for nearly all purchases and two customers accounting for the vast majority of revenue. The company has experienced net losses since inception and faces liquidity challenges, with a current ratio of 0.31 as of December 31, 2025. CIMG is listed on Nasdaq but has faced compliance issues related to listing standards. The company is expanding its presence in the Chinese market through new agreements and a significant sales contract. It also completed an acquisition involving subsidiaries in Hong Kong and the British Virgin Islands. Regulatory risks include evolving data security and antimonopoly laws in Hong Kong and complex regulatory requirements in China, including approvals for overseas securities offerings. The company’s future performance depends on successful product innovation, managing growth, and securing additional capital.

Netcapital Inc. is a Nasdaq-listed company engaged primarily in funding portal operations and is developing broker-dealer services focused on Regulation A and D offerings. The company has recently acquired assets related to digital design and blockchain cybersecurity technology. Financial disclosures indicate low revenue relative to operating losses and constrained liquidity. The company faces significant customer concentration and regulatory risks, and its financial condition raises concerns about ongoing viability without additional financing.

Odysight.ai Inc. develops and markets advanced AI-powered visual monitoring solutions that deploy miniature vision-based sensors to monitor critical safety components in hard-to-reach and harsh environments. The company's solutions provide real-time data streaming to an AI/ML processing unit, enabling predictive maintenance and condition-based monitoring across civil and defense sectors. Its technology enhances safety, reduces downtime, and improves operational efficiency by delivering real-time failure detection and predictive insights. Odysight.ai's products are deployed in aerospace platforms such as UAVs and helicopters, as well as industrial applications including elevator monitoring and transportation systems. The company operates a business model combining initial hardware sales with plans for recurring software subscription revenues. It holds a broad patent portfolio and is led by an experienced management team. Odysight.ai is expanding its market presence globally, focusing on aerospace while targeting Industry 4.0 and other verticals.

SilverBox Corp IV operates as a Special Purpose Acquisition Company (SPAC) with the primary objective of completing a business combination with Parataxis Holdings, a company focused on bitcoin-native institutional digital asset management and digital asset treasury services. The combination aims to bring Parataxis Holdings public, leveraging SilverBox's status as a publicly traded entity. The business model post-combination centers on digital asset management, including bitcoin treasury and mining platforms, with a geographic focus on South Korea. The company has announced definitive agreements and reached key milestones related to this combination and expansion into the South Korean market. Financial disclosures indicate a net income of approximately $5.7 million for the fiscal year ending 2025, but liquidity ratios suggest limited current asset coverage against liabilities as of year-end 2025.

Strawberry Fields REIT, Inc. operates as a real estate investment trust specializing in healthcare properties, including skilled nursing facilities, long-term acute care hospitals, and assisted living facilities across multiple U.S. states. The company generates revenue primarily through rental income from these properties under triple-net leases. It manages tenant relationships and monitors credit risk, maintaining allowances for doubtful accounts. The company is classified as an emerging growth company and operates as a single segment focused on healthcare real estate. It holds significant real estate assets and finances operations through bonds, senior debt, and notes payable. The company has a small employee base and requires tenants to maintain insurance coverage naming the company as additional insured. Legal proceedings related to property acquisitions have been ongoing but recent court decisions have dismissed claims with prejudice [S1][S9][S7].

Strive, Inc. operates as a structured finance company and institutional asset manager focused on disciplined capital allocation with a strategic emphasis on bitcoin as a benchmark for investment decisions. The company aims to create long-term value for stockholders by growing its bitcoin holdings and managing its balance sheet prudently. Strive's operating business includes the issuance of SATA Stock, a perpetual preferred equity instrument with an at-the-market program designed to provide flexible capital formation. The company became publicly traded following a reverse acquisition in September 2025 and manages over $2.4 billion in assets under management as of year-end 2025. Strive's bitcoin strategy involves acquiring bitcoin through open market purchases and strategic transactions, including M&A, to obtain bitcoin at discounts. The company holds its bitcoin with multiple institutional custodians employing strict security protocols. In addition to bitcoin treasury management, Strive owns Semler Scientific, a healthcare technology business marketing the FDA-cleared QuantaFlo vascular testing product. The company reported a net loss in 2025, driven by investment losses and impairments related to digital assets, but maintains strong liquidity and capital resources to support its strategic initiatives [S1].

Coeptis Therapeutics Holdings, Inc. is a Nasdaq-listed emerging growth company involved in biopharmaceutical and technology sectors. The company has recently pursued a merger with Z Squared Inc. to enter the Dogecoin mining space, indicating diversification beyond its biopharmaceutical operations. It has established GEAR Therapeutics to advance cancer cell therapy and secured worldwide rights to the GEAR platform. Additionally, Coeptis has formed strategic partnerships to enhance AI integration in defense, security, and marketing solutions, and launched a venture group to invest in AI and automation startups. The company has also strengthened its capital structure by extinguishing a convertible note and implemented an option repricing program for equity incentives. Financially, the company reported revenue of $1.36 million and a net loss of $11.9 million for the fiscal year ending December 31, 2025, with liquidity ratios indicating a strong current ratio of 4.16 [N1,N2,N4,N6,N7,N8,S1].